Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer: a phase II trial of the EORTC-New Drug Development Group

Autor: Giaccone, G, Smit, E.F, de Jonge, M, Dansin, E, Briasoulis, E, Ardizzoni, A, Douillard, J.-Y, Spaeth, D, Lacombe, D, Baron, B, Bachmann, P, Fumoleau, P
Zdroj: In European Journal of Cancer 2004 40(5):667-672
Databáze: ScienceDirect
Externí odkaz: